See the latest news and media coverage for Nektar. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing autoimmune and inflammatory therapies
nektar.comLast updated
In short: Nektar launched a Phase 3 program for rezpegaldesleukin in atopic dermatitis following positive trial data and successful capital raises.
The program includes three global trials evaluating rezpegaldesleukin in moderate-to-severe atopic dermatitis, with initial data expected in mid-2028 and BLA submission targeted for 2029.
Cash reaches $731.6M. Revenue $10.9M, net loss $44.9M. Advances rezpegaldesleukin Phase 3 trials. Raises $373.8M in offering.
The offering includes full exercise of underwriters' option for additional shares sold at $92.00 per share. Gross proceeds are approximately $373.8 million before expenses.
Sells 3,532,609 shares at $92 each. Proceeds fund R&D, clinical trials, manufacturing. Closes April 23, 2026.
Nektar gains a clearer path in atopic dermatitis after Sanofi halts amlitelimab development, removing a major competitor. Read more on NKTR stock here.
Nektar begins two phase III ZENITH AD studies of rezpeg for moderate-to-severe atopic dermatitis,...
In the second half of 2026, Nektar also plans to present more data from its mid-stage eczema study, particularly how well improvements are sustained on...
This clinical-stage biopharma focused on oncology and immunology reported a notable insider sale as pipeline programs advance.
Track Nektar and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Nektar and other trending companies.